Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2
- Conditions
- diffuse large B cell lymphoma
- Registration Number
- JPRN-UMIN000037528
- Lead Sponsor
- Department of Radiology, Juntendo University Hospital, Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
Primary central nervous system lymphoma, primary cutaneous DLBCL, leg type, T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, or other distinct non-Hodgkin lymphomas arising from large B-cells included in the WHO classification Any absolute contraindications to irradiation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine if high rates of local control can be maintained after a reduction in the RT dose (from 30 Gy to 20 Gy) after 3 to 6 cycles of chemo-immunotherapy.
- Secondary Outcome Measures
Name Time Method To determine disease-free survival and overall survival after chemotherapy and low-dose (20 Gy) consolidation radiation therapy. To identify patterns of failure after combined modality therapy using lower doses of consolidation RT